Richard Mair joins Institute as an Independent Clinical Fellow
Richard Mair has joined the Cancer Research UK Cambridge Institute as an Independent Clinical Fellow.
Dr Richard Mair is the first to be appointed under the Institute’s new Independent Clinical Fellow Programme, which supports clinician scientists in establishing themselves as independent clinical academics and future leaders in their field.
The programme provides fellows with access to world-class research facilities, dedicated mentorship, and operational support, enabling them to build their own research groups and advance translational cancer research.
Richard is Assistant Professor of Neurosurgical Oncology at the University of Cambridge and an Honorary Consultant Neurosurgeon at Addenbrooke’s Hospital. He leads several key initiatives, including the Minderoo Precision Brain Tumour Programme, the Brain Cancer Virtual Institute at the CRUK Cambridge Centre and the ICARUS tissue bank.
Supported by a Cancer Research UK Advanced Clinician Scientist Fellowship, Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Astrocytoma typically presents as a slow growing, low-grade tumour, before undergoing a transformation to a high-grade, fast-growing tumour. Once this transformation occurs, the average patient survival is approximately 2 years.
Richard and his team at the Institute will investigate why astrocytoma transforms from a low-grade to a high-grade tumour. Their work will particularly focus on metabolic and epigenomic interplay in this process. They aim to identify key genes that drive transformation and to develop novel therapeutic strategies that could improve patient outcomes.
“We are delighted to welcome Dr Richard Mair as the first fellow appointed under our Independent Clinical Fellow Programme. Through his leadership in the Minderoo Precision Brain Tumour Programme as well as his work on the 5G platform trial, Richard has demonstrated a strong drive to bridge cutting-edge research with real-world clinical impact. His track record of translating discoveries into real benefits for patients makes him an outstanding addition to the Institute, and we are excited to support him as he builds his research group to further advance brain tumour research.”
Dr Raza Ali, Associate Director for Clinical Academic Training
Related News
See all news-
Dr Richard Mair to co-lead £13.7M investment for brain tumour research
19th December 2025
The National Institute for Health and Care Research (NIHR) has today announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.
Find out more -
Order of cancer-driving mutations affects the chance of tumour development
3rd December 2025
New research from the Winton Group has revealed that the order of cancer-driving mutations plays an important role in whether tumours in the intestine can develop.
Find out more -
Cancer Detectives: New Channel 4 Documentary Showcases Cambridge Brain Cancer Trial
27th November 2025
A Cambridge researcher offering new hope to people with brain tumours is the focus of a documentary exploring the science behind the next big breakthroughs.
Find out more